RBFOX2 is required for establishing RNA regulatory networks essential for heart development;
Verma, SK, Deshmukh, V, Thatcher, K, Belanger, KAK, Rhyner, AM, Meng, S, Holcomb, RJ, Bressan, M, Martin, JF, Cooke, JP, Wythe, JD, Widen, SG, Lincoln, J & Kuyumcu-Martinez, MN 2022, , Nucleic Acids Research, vol. 50, no. 4, pp. 2270-2286.

RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases;
Bejar, N, Tat, TT & Kiss, DL 2022, , Current Atherosclerosis Reports, vol. 24, no. 5, pp. 307-321.

Free Cholesterol Bioavailability and Atherosclerosis;
Abe, RJ, Abe, JI, Nguyen, MTH, Olmsted-Davis, EA, Mamun, A, Banerjee, P, Cooke, JP, Fang, L, Pownall, H & Le, NT 2022, , Current Atherosclerosis Reports, vol. 24, no. 5, pp. 323-336.

Emerging nanotechnologies in cardiovascular medicine;
Grattoni, A & Cooke, JP 2022, , Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 39, 102472.

Hospital-Based RNA Therapeutics;
Damase, TR, Sukhovershin, R, Zhang, M, Kiss, DL & Cooke, JP 2021, . in mRNA Therapeutics: Springer.

Unsupervised learning for automated detection of coronary artery disease subgroups;
Flores, AM, Schuler, A, Eberhard, AV, Olin, JW, Cooke, JP, Leeper, NJ, Shah, NH & Ross, EG 2021, , Journal of the American Heart Association, vol. 10, no. 23, e021976.

Disturbed flow-induced FAK K152 SUMOylation initiates the formation of pro-inflammation positive feedback loop by inducing reactive oxygen species production in endothelial cells;
Velatooru, LR, Abe, RJ, Imanishi, M, Gi, YJ, Ko, KA, Heo, KS, Fujiwara, K, Le, NT & Kotla, S 2021, , Free Radical Biology and Medicine, vol. 177, pp. 404-418.

Precision delivery of liquid therapy into the arterial wall for the treatment of peripheral arterial disease;
Atigh, MK, Goel, E, Erwin, M, Greer, R, Ohayon, J, Pettigrew, RI & Yazdani, SK 2021, , Scientific Reports, vol. 11, no. 1, 18676.